Estrella Immunopharma (ESLA) Operating Expenses (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Operating Expenses for 6 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 62.41% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $9.8 million, a 50.73% decrease from a year earlier, with the FY2025 full-year figure at $13.1 million, up 47.67% from the prior year.
• Operating Expenses was $2.1 million for Q2 2026 at Estrella Immunopharma, down from $2.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $8.4 million in Q1 2023 and troughed at $120740.0 in Q1 2022.
• A 5-year average of $3.1 million and a median of $2.2 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 27343.83% in 2022 and plunged 94.4% in 2024, its largest moves.
• Over 5 years, Operating Expenses stood at $5.6 million in 2022, then slumped by 81.91% to $1.0 million in 2023, then soared by 333.75% to $4.4 million in 2024, then sank by 86.15% to $613199.0 in 2025, then soared by 239.9% to $2.1 million in 2026.
• The last three Operating Expenses figures came in at $2.1 million (Q2 2026), $2.3 million (Q1 2026), and $613199.0 (Q4 2025), per Business Quant data.